Product
BNT162b2
Aliases
Biological/Vaccine: BNT162b2 10mcg, bivalent BNT162b2 (original/Omi BA.4/BA.5), BNT162b2 20mcg, BNT162b2 30mcg (13 other aliases)
43 clinical trials
25 indications
Indication
COVID-19Indication
InfluenzaIndication
HumanIndication
ImmunocompromisedIndication
ImmunosuppressedIndication
Breakthrough InfectionIndication
SARS-CoV-2Indication
pneumococcal diseaseIndication
severe acute respiratory syndromeIndication
Maternal ImmunizationIndication
COVID-19 VaccineIndication
Chronic Liver DiseaseIndication
HealthyIndication
ImmunizationIndication
CancerIndication
COVID-19 VaccinationIndication
Rheumatoid ArthritisIndication
Systemic Lupus Erythematosus (SLE)Indication
Pemphigus vulgarisIndication
Multiple SclerosisIndication
Systemic SclerosisIndication
Pediatric Systemic Lupus ErythematosusIndication
Juvenile Idiopathic Arthritis (JIA)Indication
Juvenile DermatomyositisClinical trial
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong KongStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
Vaccine Effectiveness Study of Pfizer-BNT Vaccines - Kaiser Permanente Southern CaliforniaStatus: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA COVID-19 Vaccine and a Recombinant Influenza Vaccine Administered as a Single Injection in Healthy Adults 50 Years of Age or OlderStatus: Active (not recruiting), Estimated PCD: 2024-09-05
Clinical trial
An Exploratory Phase I, Randomized, Observer-blind, Active-controlled, Dose-escalation Trial Evaluating the Safety, Tolerability, and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Healthy AdultsStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Coronavirus Disease 2019 (COVID-19) Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United StatesStatus: Completed, Estimated PCD: 2021-12-17
Clinical trial
A PHASE 2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED VACCINE CANDIDATES FOR SARS-CoV-2 NEW VARIANTS IN HEALTHY INDIVIDUALSStatus: Active (not recruiting), Estimated PCD: 2024-12-09
Clinical trial
A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDRENStatus: Recruiting, Estimated PCD: 2025-08-11
Clinical trial
A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDRENStatus: Completed, Estimated PCD: 2023-10-04
Clinical trial
A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALSStatus: Completed, Estimated PCD: 2023-12-28
Clinical trial
AN INTERVENTIONAL, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 1/2/3 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b RNA-BASED VACCINE CANDIDATES IN COVID-19 VACCINE-EXPERIENCED HEALTHY INDIVIDUALSStatus: Completed, Estimated PCD: 2024-03-26
Clinical trial
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2Status: Completed, Estimated PCD: 2023-05-25
Clinical trial
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTSStatus: Completed, Estimated PCD: 2021-11-25
Clinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGEStatus: Completed, Estimated PCD: 2021-12-01
Clinical trial
Safety Profile of BNT162b2 mRNA SARS-Cov-2 Vaccine in Indonesia: A National Passive Surveillance.Status: Completed, Estimated PCD: 2023-04-03
Clinical trial
A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 VaccineStatus: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALSStatus: Completed, Estimated PCD: 2023-02-10
Clinical trial
A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDERStatus: Completed, Estimated PCD: 2021-12-08
Clinical trial
General Investigation of COMIRNATY Intramuscular Injection (Follow-up Study for Subjects [Healthcare Professionals] Who Are Vaccinated at an Early Post-Approval Stage)Status: Completed, Estimated PCD: 2023-01-27
Clinical trial
A Phase II, Open-label, Rollover Trial to Evaluate the Safety and Immunogenicity of One or Two Boosting Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 Trial Subjects, or Two Boosting Doses of Comirnaty in BNT162-04 Trial SubjectsStatus: Completed, Estimated PCD: 2022-04-14
Clinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF BNT162b2 WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE (SIIV) IN ADULTS 18 THROUGH 64 YEARS OF AGEStatus: Completed, Estimated PCD: 2022-10-05
Clinical trial
Immunogenicity, Efficacy and Safety of Inhaled (IH) Viral Vectored Vaccine (Convidecia, CanSino) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections. A Randomized Observer-blind Controlled Trial.Status: Completed, Estimated PCD: 2023-05-02
Clinical trial
A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGEStatus: Completed, Estimated PCD: 2023-07-23
Clinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGEStatus: Completed, Estimated PCD: 2021-07-22
Clinical trial
A Phase II Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Monovalent and Multivalent RNA-based Vaccines in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-08-16
Clinical trial
A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDERStatus: Completed, Estimated PCD: 2022-07-15
Clinical trial
mRNA Vaccination to Boost Antibodies Against SARS-CoV-2 in Recipients of Inactivated Vaccines (the "mBoost" Study)Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 VaccinesStatus: Completed, Estimated PCD: 2023-09-30
Clinical trial
Phase II/III Double-blind, Randomized Clinical Trial With Active Vaccine Control to Evaluate the Safety, Immunogenicity, and Consistency of the Lots of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine in Adults in BrazilStatus: Active (not recruiting), Estimated PCD: 2023-10-05
Clinical trial
Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is "Mix and Match" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesStatus: Completed, Estimated PCD: 2023-06-16
Clinical trial
Assessment of the Immunogenicity and Safety of Marketed Vaccines for COVID-19 After Regular Schedule and Adapted Vaccine Schedules and Routes: BNT162b2, mRNA-1273 Vaccine and ChAdOx1-S [Recombinant]Status: Completed, Estimated PCD: 2021-11-03
Clinical trial
A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of VaccineStatus: Completed, Estimated PCD: 2021-06-30
Clinical trial
Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy AdultsStatus: Completed, Estimated PCD: 2023-07-28
Clinical trial
Fourth BNT162b2 COVID-19 Vaccine Dose - the Sheba HCW CohortStatus: Active (not recruiting), Estimated PCD: 2024-06-26
Clinical trial
Safety and Efficacy of Booster Doses of BNT162b2 Vaccine in Immunocompromised Patients With a Cancer DiagnosisStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Blood Donations From Healthy Probands for the Study of the Adaptive Immune Response to COVID-19 Vaccination (AICOVI)Status: Active (not recruiting), Estimated PCD: 2021-12-13
Clinical trial
SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 PatientsStatus: Completed, Estimated PCD: 2022-12-21
Clinical trial
A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant RecipientsStatus: Terminated, Estimated PCD: 2022-10-25
Clinical trial
Phase 2 Clinical Trial to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging VariantsStatus: Completed, Estimated PCD: 2023-11-22
Clinical trial
Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign Among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCSStatus: Completed, Estimated PCD: 2021-03-31
Clinical trial
Immunogenicity, Safety and Tolerability of Intradermal COVID-19 Vaccination Strategy in Immunocompromised Patients: a Prospective, Randomized Trial.Status: Recruiting, Estimated PCD: 2023-03-31
Clinical trial
Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)Status: Completed, Estimated PCD: 2023-06-22
Clinical trial
Special Investigation of COMIRNATY Intramuscular Injection (Investigation of Patients With Underlying Disease Considered to be at High Risk of Aggravation of COVID-19)Status: Completed, Estimated PCD: 2022-04-14